Aktuelle Leitlinie zur Therapie der Uveitis bei juveniler idiopathischer Arthritis

A. Heiligenhaus; K. Minden; C. Tappeiner; H. Lehmann; Leitliniengruppe

doi:10.1055/s-0038-1637691

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2018; 38(01): 50-55
DOI: 10.1055/s-0038-1637691

Kinderrheumatologie

Schattauer GmbH

Aktuelle Leitlinie zur Therapie der Uveitis bei juveniler idiopathischer Arthritis

Current treatment guideline on uveitis in juvenile idiopathic arthritis

A. Heiligenhaus

¹F.E.B.O., Uveitis-Zentrum, Augenzentrum am St. Franziskus Hospital, Münster

,

K. Minden

²Charité – Universitätsmedizin Berlin, Medizinische Klinik mit SP Rheumatologie und Klinische Immunologie und Deutsches Rheumaforschungszentrum, Berlin

,

C. Tappeiner

³F.E.B.O., Universitätsklinik für Augenheilkunde, Inselspital, Bern, Schweiz

,

H. Lehmann^*

⁴Allgemeine Pädiatrie und Rheumatologie, Universitätsklinikum Gießen

,

Leitliniengruppe

› Author Affiliations

Abstract

Zusammenfassung

Zielsetzung: Aktualisierung der bestehenden deutschsprachigen interdisziplinären Leitlinie zur Therapie der juvenilen idiopathischen Arthritis (JIA)-assoziierten Uveitis aufgrund der aktuellen Literatur.

Material und Methoden: Die Leitliniengruppe bestand aus Delegierten der Deutschen Ophthalmologischen Gesellschaft, der Gesellschaft für Kinder- und Jugendrheumatologie, der Deutschen Gesellschaft für Rheumatologie, des Berufsverbandes der Augenärzte Deutschlands und Patientenvertretern. Die Methodik umfasste eine systematische Literaturrecherche, eine Graduierung von Evidenz und Empfehlungen, eine Konsensusfindung mittels nominalem Gruppenprozess und Delphirunden und eine externe Begutachtung.

Ergebnisse: Entsprechend dem individuellen Schweregrad der Uveitis kann eine qualitative hochwertige Versorgung der Patienten erzielt werden. Berücksichtigung finden Kortikosteroide, konventionell synthetische (cs) und biologische (b) disease-modifying anti-rheumatic drugs (DMARDs), einschließlich TNF-α-Inhibitoren (z. B. Adalimumab, Golimumab, Infliximab), Tocilizumab, Abatacept und Rituximab.

Schlussfolgerungen: Mit der Leitlinie wird ein aktueller Therapiealgorithmus mit Darstellung als Flussdiagramm erarbeitet.

Summary

Goal: Revision of the German interdisciplinary guideline on the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis with appreciation of recently published data.

Material and methods: The guideline group comprised delegates from German Ophthalmological Society, Society for Child and Adolescent Rheumatology, German Society of Rheumatology, Professional Association of Ophthalmologists, and patient representatives. Methods included systematic literature survey, gradation of evidence and recommendations, consensus process (Delphi procedure), and external review.

Results: Adjusted to disease severity in the individual case, a high-quality patient care can be ensured. Corticosteroids, conventional synthetic (cs) and biological (b) disease-modifying anti-rheumatic drugs (DMARDs) are taken into account, including TNFα inhibitors (e. g. adalimumab, golimumab, infliximab), tocilizumab, abatacept and rituximab.

Conclusions: Within the guideline, a current treatment algorithm with presentation as flow diagrams is established.

Schlüsselwörter

Juvenile idiopathische Arthritis - Therapie - Uveitis

Keywords

Juvenile idiopathic arthritis - treatment - uveitis

Full Text

References

Literatur
1 Heiligenhaus A, Niewerth M, Ganser G. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nationwide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015-1019.
2 Kotaniemi K, Kautiainen H, Karma A. et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071-2075.
3 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.
4 De Boer J, Steijaert A, van den Bor R. et al. Development of macular edema and impact and visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67-73.
5 Böhm MR, Tappeiner C, Breitbach MA. et al. Ocular hypotony in patients with juvenile idiopathic arthritis- associated uveitis. Am J Ophthalmol 2017; 173: 45-55.
6 Thorne JE, Woreta FA, Dunn JP. et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436-1441.
7 Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485.
8 De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884.
9 Heiligenhaus A, Michels H, Schumacher C. et al. Evidence-based guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012; 32: 1121-1133.
10 Kothari S, Foster CS, Pistilli M. et al. The risk of intraocular pressure elevation in pediatric non-infectious uveitis. Ophthalmology 2015; 122: 1987-2001.
11 Tappeiner C, Klotsche J, Schenck S. et al. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-944.
12 Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365.
13 Heiligenhaus A, Mingels A, Heinz C. et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748.
14 Samson CM, Waheed N, Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139.
15 Kostik MM, Gaidar EV, Hynnes AY. et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol 2016; 34: 714-718.
16 Papadopoulou C, Kostik M, Böhm M. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-884.
17 Tappeiner C, Schenck S, Niewerth M. et al. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res 2016; 68: 46-54.
18 Lerman MA, Burnham JM, Chang PY. et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013; 40: 1394-1403.
19 Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200.
20 Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 2014; 22: 96-101.
21 Simonini G, Druce K, Cimaz R. et al. Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66: 1073-1084.
22 Vallet H, Seve P, Biard L. et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 2016; 68: 1522-1530.
23 Beukelman T, Ringold S, Davis TE. et al. Diseasemodifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39: 1867-1874.
24 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopahic arthritis. N Engl J Med 2017; 376: 1637-1646.
25 Diaz-Llopis M, Salom D, Garcia-de-Vicuna C. et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-1581.
26 Zannin ME, Birolo C, Gerloni VM. et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013; 40: 74-79.
27 Cordero-Coma M, Calvo-Rio V, Adan A. et al. Golimumab as rescue therapy for refractory immunemediated uveitis: a three-center experience. Mediators Inflamm 2014; 2014: 717598.
28 Miserocchi E, Modorati G, Pontikaki I. et al. Longterm treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90-95.
29 Tynjälä P, Lindahl P, Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550.
30 Saurenmann RK, Levin AV, Feldman BM. et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833-836.
31 Scrivo R, Spadaro A, Spinelli FR. et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-1556.
32 Calvo-Rio V, Santos-Gomez M, Calvo I. et al. Anti- IL-6R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy. A multicenter study of 25 patients. Arthritis Rheumatol 2016; 69: 668-675.
33 Tappeiner C, Mesquida M, Adan A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43: 2183-2188.
34 Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 2008; 35: 1897-1898.
35 Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Arthritis Care Res 2011; 63: 307-310.
36 Tappeiner C, Miserocchi E, Bodaghi B. et al. Abatacept in the treatment of severe, longstanding and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706-711.
37 Heiligenhaus A, Miserocchi E, Heinz C. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390-1394.
38 Miserocchi E, Pontikaki I, Modorati G. et al. Rituximab for uveitis. Ophthalmology 2011; 118: 223-224.
39 Miserocchi E, Modorati G, Berchicci L. et al. Longterm treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016; 100: 782-786.
40 Kalinina VKAyuso, van de Winkel EL, Rothova A. et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-222.